Brevan Howard Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Brevan Howard Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-170,928	Closed	-$2.37M	–	2044
2026 Q1	$2.37M	Sell	170,928 -199,748	-54%	-$3.18M	0.02%	487
2025 Q4	$6.03M	Buy	370,676 +354,234	+2,154%	+$5.78M	0.07%	196
2025 Q3	$246K	Buy	+16,442	New	+$200K	﹤0.01%	1662
2025 Q2	–	Sell	-60,213	Closed	-$447K	–	1824
2025 Q1	$447K	Buy	60,213 +35,152	+140%	+$270K	﹤0.01%	754
2024 Q4	$150K	Buy	+25,061	New	+$138K	﹤0.01%	940

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Brevan Howard Capital Management's ADPT Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 170,928 shares — an estimated $2.37M sold.

Brevan Howard Capital Management first reported a position in ADPT in Q4 2024 and held it in 5 quarters. The position peaked at $6.03M in Q4 2025. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Brevan Howard Capital Management reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
Brevan Howard Capital Management sold 170,928 Adaptive Biotechnologies shares in Q2 2026, an estimated $2.37M.
Brevan Howard Capital Management first reported a position in Adaptive Biotechnologies in Q4 2024 and held it in 5 quarters.
Brevan Howard Capital Management's Adaptive Biotechnologies position peaked at $6.03M in Q4 2025.
300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.